secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvalent, Inc. (NUVL)
CIK:        0001861560
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001193125-26-073304
Event type: earnings
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvalent reports Q4 and FY2025 net loss; zidesamtinib PDUFA set for Sept 18, 2026
--------------------------------------------------------------------------------

- Net loss of $118.7M in Q4 2025 and $425.4M for full year 2025.
- Cash, equivalents and marketable securities of $1.4B, runway into 2029.
- FDA accepted zidesamtinib NDA; PDUFA target action date September 18, 2026.
- NDA submission for neladalkib in ALK+ NSCLC planned first half 2026.
- Closed $500M public offering of common stock in November 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1861560/000119312526073304/0001193125-26-073304-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1861560/000119312526073304/nuvl-20260226.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-073304

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer